This is the development pipeline as of Apr. 22, 2024
1. Oncology
As of Apr. 22, 2024
| Product Name/ Development Code/ Generic Name |
Mechanism | Dosage Form | Target Indication | Phase* | Area | Licensor | |||
|---|---|---|---|---|---|---|---|---|---|
| Ⅰ | Ⅱ | Ⅲ | F | ||||||
| Opdivo Intravenous Infusion |
Anti-PD-1 antibody | Injection | Hepatocellular carcinoma |
|
JP・KR | In-house (Co-developed with BMS) |
|||
| Ovarian cancer |
|
JP・KR・TW | |||||||
| Bladder cancer |
|
JP・KR・TW | |||||||
| Braftovi Capsules |
BRAF inhibitor | Capsule | Thyroid cancer |
|
JP | Pfizer | |||
| Mektovi Tablets |
MEK inhibitor | Tablet | Thyroid cancer |
|
JP | Pfizer | |||
| Yervoy Injection★ |
Anti-CTLA-4 antibody | Injection | Gastric cancer |
|
JP・KR・TW | Co-developed with BMS | |||
| Urothelial cancer |
|
JP・KR・TW | |||||||
| Hepatocellular carcinoma |
|
JP・KR | |||||||
| ONO-7913/ Magrolimab |
Anti-CD47 antibody | Injection | Pancreatic cancer★ |
|
JP | Gilead | |||
| Colorectal cancer★ |
|
JP | |||||||
| ONO-4482★/ Relatlimab |
Anti-LAG-3 antibody | Injection | Melanoma |
|
JP | Co-developed with BMS | |||
| Hepatocellular carcinoma |
|
JP・KR・TW | |||||||
| ONO-7475/ Tamnorzatinib |
Axl/Mer inhibitor | Tablet | Pancreatic cancer★ |
|
JP | In-house | |||
| EGFR-mutated non-small cell lung cancer |
|
JP | |||||||
| ONO-4578 | PG receptor (EP4) antagonist | Tablet | Gastric cancer★ |
|
JP・KR・TW | In-house | |||
| Colorectal cancer★ |
|
JP | |||||||
| Pancreatic cancer★ |
|
JP | |||||||
| Non-small cell lung cancer★ |
|
JP | |||||||
| Hormone receptor-positive, HER2-negative breast cancer |
|
JP | |||||||
| ONO-7427★ | Anti-CCR8 antibody | Injection | Solid tumor |
|
JP・US・EU | Co-developed with BMS | |||
| ONO-7914★ | STING agonist | Injection | Solid tumor |
|
JP | In-house | |||
| ONO-4059 | Bruton‘s tyrosine kinase (BTK) inhibitor | Tablet | Primary central nervous system lymphoma |
|
US | In-house | |||
| ONO-4685 | PD-1×CD3 bispecific antibody | Injection | T-cell lymphoma |
|
JP・US | In-house | |||
| ONO-7018 | MALT1 inhibitor | Tablet | Non-Hodgkin lymphoma, Chronic lymphocytic leukemia |
|
US | Chordia | |||
| ONO-4538HSC | Anti-PD-1 antibody | Injection | Solid tumor |
|
JP | Co-developed with BMS | |||
| ONO-8250 | iPSC-derived HER2 CAR T-cell therapy | Injection | HER2-expressing Solid tumor |
|
US | Fate | |||
★Combination with Opdivo.
※In the case of clinical development of the oncology drugs in the same indication, the most advanced clinical phase is described.
- Ⅰ:Phase 1、Ⅱ:Phase 2、Ⅲ:Phase 3:、F:Filed
2. Areas other than Oncology
As of Apr. 22, 2024
| Product Name/ Development Code/ Generic Name |
Mechanism | Dosage Form | Target Indication | Phase* | Area | Licensor | |||
|---|---|---|---|---|---|---|---|---|---|
| Ⅰ | Ⅱ | Ⅲ | F | ||||||
| Velexbru Tablets/ Tirabrutinib Hydrochloride |
Bruton‘s tyrosine kinase (BTK) inhibitor | Tablet | Pemphigus |
|
JP | In-house | |||
| ONO-2017/ Cenobamate |
Inhibition of voltage-gated sodium currents/positive allosteric modulator of GABAA ion channel | Tablet | Primary generalized tonic-clonic seizures |
|
JP | SKBP | |||
| Partial-onset seizures |
|
JP | |||||||
| ONO-2910 | Enhancement of Schwann cell differentiation | Tablet | Chemotherapy-Induced Peripheral Neuropathy |
|
JP | In-house | |||
| Diabetic polyneuropathy |
|
JP | |||||||
|
|
US | ||||||||
| ONO-2808 | S1P5 receptor agonist | Tablet | Multiple System Atrophy |
|
JP・US | In-house | |||
| ONO-4685 | PD-1×CD3 bispecific antibody | Injection | Autoimmune disease |
|
JP・EU | In-house | |||
| ONO-2020 | Epigenetic Regulation | Tablet | Neurodegenerative disease |
|
US | In-house | |||
| ONO-1110 | Endocannabinoid regulation | Oral | Pain |
|
JP | In-house | |||
- Ⅰ:Phase 1、Ⅱ:Phase 2、Ⅲ:Phase 3:、F:Filed